Welcome to our dedicated page for Vigil Neuroscience SEC filings (Ticker: VIGL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking a microglia-focused biotech means wading through technical disclosures, from pre-clinical data tables to FDA correspondence buried deep in appendices. Vigil Neuroscience’s SEC documents are no exception—its annual report details R&D expenses tied to TREM2 agonists, while 8-K releases often announce early efficacy readouts. If you have ever searched for “Vigil Neuroscience SEC filings explained simply,” you know how time-consuming it is to locate the exact trial milestone or cash-runway figure.
Stock Titan solves that problem. Our AI scans every “Vigil Neuroscience quarterly earnings report 10-Q filing,” parses scientific terminology and flags what matters: fresh safety signals, phase-transition timelines and dilution risk. Need “Vigil Neuroscience Form 4 insider transactions real-time”? We alert you the moment an executive buys or sells shares, helping you compare confidence levels across development stages. The same engine delivers concise digests of the “Vigil Neuroscience annual report 10-K simplified,” highlights segment spending, and links directly to tables on R&D burn.
All filing types are covered and updated the instant EDGAR posts them: 10-K, 10-Q, 8-K, S-3, SC 13G and the “Vigil Neuroscience proxy statement executive compensation.” Use AI-powered summaries to interpret “Vigil Neuroscience insider trading Form 4 transactions,” evaluate liquidity in seconds with “Vigil Neuroscience earnings report filing analysis,” or quickly review “Vigil Neuroscience 8-K material events explained.” With Stock Titan you are not just downloading PDFs—you are understanding Vigil Neuroscience SEC documents with AI and turning dense neuroscience jargon into actionable insight.
Vigil Neuroscience, Inc. Schedule 13G/A filed by a group of related entities led by Biotechnology Value Fund and Mark N. Lampert reports that, as of the close of business on June 30, 2025, the Reporting Persons no longer beneficially owned any shares of Vigil Neuroscience common stock (CUSIP 92673K108). The filing lists each reporting entity, their jurisdictions (mostly Delaware, some Cayman Islands), the reporting address for BVF entities, and confirms zero sole or shared voting and dispositive power for all listed persons. The statement is signed by Mark N. Lampert on behalf of the reporting entities on August 14, 2025.
Glazer Capital, LLC and Paul J. Glazer reported beneficial ownership of 3,012,068 shares of Vigil Neuroscience common stock, representing 6.45% of the class as of the reporting event date 06/30/2025. The filing indicates the Reporting Persons have shared voting and shared dispositive power over these shares and no sole voting or dispositive power. The statement identifies Glazer Capital as an investment manager and Mr. Glazer as its managing member and includes the issuer's principal office in Watertown, MA. The Reporting Persons certify the shares were not acquired to change or influence control of the issuer. The filing is signed 08/14/2025.
Vigil Neuroscience, Inc. (VIGL) submitted Post-Effective Amendments to four outstanding Form S-8 registration statements after completing its 5 Aug 2025 merger with Sanofi. The merger converted Vigil into a wholly owned Sanofi subsidiary, triggering automatic termination of all employee-equity offerings covered by the S-8s.
The amendments deregister every share that remained unissued under the company’s: (1) Amended & Restated 2020 Equity Incentive Plan, (2) 2021 Stock Option & Incentive Plan, (3) 2021 Employee Stock Purchase Plan, and (4) a 330,000-share inducement option. The four S-8s had originally registered a combined 12 million+ common shares between 2022 and 2025. By filing the amendments, Vigil formally removes those unsold shares from SEC registration, eliminating potential dilution and closing out the plans. No financial metrics, earnings data or forward-looking statements are included in the filing.
Vigil Neuroscience (VIGL) – Form 4 (08/05/25): Director Mary Thistle reports the disposition of 5,000 common shares and the cash-out of 68,460 in-the-money stock options/RSUs at the closing of Vigil’s merger with Sanofi.
At the Effective Time (5 Aug 2025), Sanofi’s Vesper Acquisition Sub merged into Vigil, making Vigil a wholly owned subsidiary. Each Vigil share outstanding was converted into (i) $8.00 cash and (ii) one contingent value right (CVR) worth up to $2.00 subject to a clinical milestone. All unvested RSUs and stock options vested immediately; options with a strike below $8.00 were cancelled for a cash payment equal to the intrinsic value plus one CVR per underlying share.
Following the conversion, Thistle holds no remaining equity in Vigil. The filing confirms consummation of the merger and the final equity treatment for insiders and, by extension, public shareholders.
FAQ
What is the current stock price of Vigil Neuroscience (VIGL)?
What is the market cap of Vigil Neuroscience (VIGL)?
